Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
This article was originally published in The Tan Sheet
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
You may also be interested in...
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track
Schering-Plough will not be able to rely on patent claims covering desloratadine to keep generic versions of its Claritin antihistamine off the OTC market before 2004 if a federal judge's ruling is upheld on appeal
Schering-Plough could be considering delaying the OTC launch of Claritin pending resolution of its underlying patent litigation for the drug